Great, so you have minimal qualifications and are just spouting something off you don't have much understanding of.
I have an M.D., and a Ph.D. in molecular biology. I live in San Diego County, and I know very well the companies you speak of. I also worked in college in one of the fore-most protein structure labs in the world. Since then, I have worked during my Ph.D. with viruses (we used them as expression vectors - I am NOT a virologist).
What I can say, for fact, is that getting the DNA and RNA sequences is the EASIEST part of all of the process of making a vaccine. Science has gotten REALLY REALLY good at sequencing DNA and RNA. It's fast, it's efficient. What we are NOT good at, and I speak from my days doing protein structure in college, is determining the 3D configuration of a protein from the DNA and RNA sequences. It's not just the LINEAR protein structure that is important, which is determined by the DNA sequence, but it is how that structure folds upon itself to form the 3D configuration of a protein which is critical (and THAT is only in part determined by the protein sequence - the environment in which the protein is expressed also determines how the protein folds). The 3D structure of a protein determines the exposed portions of the protein that the immune system can then form an immune response to (we call those exposed surfaces "epitopes"). Without epitopes that don't change much, a vaccine is dead in the water. This is why we have to create a new influenza vaccine every year - those exposed protein epitopes mutate to avoid the immune system.
Inovio has done the EASY part. At tops, 10% of the work, to create a vaccine. The hard part are Phases 1, 2, and 3 to go for.